Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients

被引：2
|
作者：
Patoulias, Dimitrios [1 ]
Papadopoulos, Christodoulos [2 ]
Stavropoulos, Konstantinos [1 ]
Imprialos, Konstantinos [1 ]
Doumas, Michael [1 ,3 ]
机构：
[1] Aristotle Univ Thessaloniki, Gen Hosp Hippokrat, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Gen Hosp Hippokrat, Dept Cardiol 3, Thessaloniki, Greece
[3] George Washington Univ, Vet Affairs Med Ctr, Washington, DC USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2020年 / 137卷
关键词：
OUTCOMES; HEALTH;
D O I：
10.1016/j.amjcard.2020.10.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：133 / 135
页数：3
相关论文
共 50 条
  • [21] Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes
    Antwi-Amoabeng, Daniel
    Beutler, Bryce D.
    Ghuman, Jasmine
    Ulanja, Mark B.
    Ghuman, Joban
    Gullapalli, Nageshwara
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [22] Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients
    Mahmoud, Tarek
    Yagan, Jude
    Hasan, Amal
    Gheith, Osama A.
    Mostafa, Mohamed
    Rida, Suzann
    El-Serwi, Nabil
    Shaker, Mohamad
    Khalid, Mahmoud
    [J]. CLINICAL TRANSPLANTATION, 2023, 37 (12)
  • [23] Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis
    Johnson, Conner E.
    Sussman, Whitney B.
    Weeda, Erin R.
    [J]. DIABETES OBESITY & METABOLISM, 2024,
  • [24] Glucose Lowering Efficacy of Glucagon-Like Peptide-1 Receptor Agonists: A Meta-Analysis
    Vilsboll, Tina
    Christensen, Mikkel
    Knop, Filip K.
    Gluud, Lise L.
    [J]. DIABETES, 2011, 60 : A295 - A295
  • [25] CARDIOVASCULAR OUTCOMES WITH SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS IN ASIANS: AN UPDATED META-ANALYSIS
    Patoulias, Dimitrios
    Katsimardou, Alexandra
    Imprialos, Konstantinos
    Stavropoulos, Konstantinos
    Toumpourleka, Maria
    Koutsampasopoulos, Konstantinos
    Mavridou, Maria
    Siskos, Fotios
    Papadopoulos, Christodoulos
    Doumas, Michael
    [J]. JOURNAL OF HYPERTENSION, 2021, 39 : E176 - E177
  • [26] Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
    Zaccardi, Francesco
    Kloecker, David E.
    Khunti, Kamlesh
    Davies, Melanie J.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (08): : 1598 - 1606
  • [27] Glucagon-like peptide-1 analogues and sodium-glucose co-transporter-2 inhibitors do not increase risk of bullous pemphigoid
    Varpuluoma, O.
    Jokelainen, J.
    Huilaja, L.
    Tasanen, K.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S155 - S155
  • [28] Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials
    Patoulias, Dimitrios
    Papadopoulos, Christodoulos
    Doumas, Michael
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (04): : 1063 - 1065
  • [29] The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis
    Ali, Muhammad Usman
    Mancini, John
    Fitzpatrick-Lewis, Donna
    Lewis, Ruth
    Jovkovic, Milos
    Zieroth, Shelley
    O'Meara, Eileen
    Connelly, Kim A.
    Sherifali, Diana
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2022, 38 (08) : 1201 - 1210
  • [30] The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
    Liu, Mingliang
    Hao, Guang
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (08) : 656 - 657
12345